NCT06260046

Brief Summary

This study is a randomized, controlled trial. A total of 48 patients will be randomized to receive sufentanil or remifentanil during robot-assisted nephrectomy surgery.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
8mo left

Started Mar 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress77%
Mar 2024Jan 2027

First Submitted

Initial submission to the registry

December 26, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 15, 2024

Completed
15 days until next milestone

Study Start

First participant enrolled

March 1, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2025

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2027

Expected
Last Updated

February 15, 2024

Status Verified

February 1, 2024

Enrollment Period

11 months

First QC Date

December 26, 2023

Last Update Submit

February 13, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • opioid consumption

    During post-anesthesia care unit(PACU) stay, until 1 hour

Secondary Outcomes (4)

  • Richmond Agitation-Sedation scale

    During post-anesthesia care unit(PACU) stay, until 1 hour

  • Incidence of postoperative nausea and vomiting

    During post-anesthesia care unit(PACU) stay, until 1 hour

  • Number of patients who administered antiemetics

    During post-anesthesia care unit(PACU) stay, until 1 hour

  • Pain score

    immediately after surgery, 15minutes, 30minutes, 60minutes after surgery

Study Arms (2)

sufentanil group

EXPERIMENTAL

sufentanil is administered for analgesic during general anesthesia

Drug: Sufentanil

remifentanil group

ACTIVE COMPARATOR

remifentanil is administered for analgesic during general anesthesia

Drug: Remifentanil

Interventions

Induction: sufentanil TCI 0.3 ng/ml Maintenance: sufentanil TCI 0.05-0.5 ng/ml

sufentanil group

Induction: remifentanil TCI 3 ng/ml Maintenance: remifentanil TCI 0.5-5 ng/ml

remifentanil group

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who undergo elective robot-assisted nephrectomy surgery
  • American Society of Anesthesiologists grade 1,2,3
  • Age \> 18 years old

You may not qualify if:

  • Refuse to participate to the study
  • Allergic history of opioid
  • chronic pain
  • opioid user before surgery
  • MAO inhibitor user
  • Severe respiratory insufficiency

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Seoul National University Bundang Hospital

Seongnam, South Korea

Location

MeSH Terms

Conditions

Pain, Postoperative

Interventions

SufentanilRemifentanil

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

FentanylPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPropionatesAcids, AcyclicCarboxylic AcidsOrganic Chemicals

Study Officials

  • Chang-Hoon Koo

    Seoul National University Bundang Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Chang-Hoon Koo

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor

Study Record Dates

First Submitted

December 26, 2023

First Posted

February 15, 2024

Study Start

March 1, 2024

Primary Completion

January 15, 2025

Study Completion (Estimated)

January 15, 2027

Last Updated

February 15, 2024

Record last verified: 2024-02

Data Sharing

IPD Sharing
Will not share

Locations